| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the CRC Department of Clinical Oncology,*
University of Nottingham Laboratory of Molecular Oncology, and the
Department of Histopathology,
City Hospital,
Nottingham; and the Division of Pathology,
School of Clinical Laboratory Sciences, University Hospital, Queens
Medical Center, Nottingham, United Kingdom
Endothelial-monocyte activating polypeptide (EMAP)-II is a novel molecule with cytokine-like pro-inflammatory properties, inducing procoagulant activity on the surface of endothelial cells and monocyte/macrophages in vitro, as well as up-regulating E- and P-selectin expression. EMAP-II is chemotactic for monocytes/macrophages and neutrophils, and stimulates myeloperoxidase release from neutrophils. Injection of EMAP-II into the mouse footpad induces an acute inflammatory response, although some regression occurs in response to direct injection of EMAP-II into murine tumors. Very little is known about the expression of EMAP-II in normal tissues of mice or humans, or about its function in vivo. We developed polyclonal antibodies against EMAP-II using recombinant protein produced in Escherichia coli, and used these antibodies to carry out an immunohistochemical study of the occurrence and distribution of EMAP-II in human tissues. The distribution of EMAP-II protein is relatively restricted, occurring primarily in endocrine organs, in cells of neuroendocrine origin, but also in tissues with high turnover. EMAP-II is strongly expressed in secretory epithelial cells of the thyroid, pancreas, adrenal and salivary glands, among others, as well as in neurons and subsets of monocytes/macrophages. It is also found in the epithelium of the small and large intestines. We conclude that EMAP-II expression is usually, but not always, associated with tissues that display high turnover and high levels of protein synthesis.
This article has been cited by other articles:
 |
|
 |
|
  B. M. Tsai, M. Wang, M. Clauss, P. Sun, and D. R. Meldrum Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2004; 287(4): R767 - R771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Murray, Y. M. Heng, P. Symonds, K. Rice, W. Ward, M. Huggins, I. Todd, and R. A. Robins Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis J. Leukoc. Biol., May 1, 2004; 75(5): 772 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Murray, P. Symonds, W. Ward, M. Huggins, A. Tiga, K. Rice, Y. M. Heng, I. Todd, and R. A. Robins Colorectal Cancer Cells Induce Lymphocyte Apoptosis by an Endothelial Monocyte-Activating Polypeptide-II-Dependent Mechanism J. Immunol., January 1, 2004; 172(1): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Lans, T. L. M. ten Hagen, R. van Horssen, P. C. Wu, S. T. van Tiel, S. K. Libutti, H. R. Alexander, and A. M. M. Eggermont Improved Antitumor Response to Isolated Limb Perfusion With Tumor Necrosis Factor After Upregulation of Endothelial Monocyte-Activating Polypeptide II in Soft Tissue Sarcoma Ann. Surg. Oncol., October 1, 2002; 9(8): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Battersby, S. C. Boddy, H. O. D. Critchley, and H. N. Jabbour Expression and Localization of Endothelial Monocyte-Activating Polypeptide II in the Human Endometrium across the Menstrual Cycle: Regulation of Expression by Prostaglandin E2 J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3928 - 3935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Chang, S. G. Park, S. Kim, and C.-Y. Kang Interaction of the C-terminal Domain of p43 and the alpha Subunit of ATP Synthase. ITS FUNCTIONAL IMPLICATION IN ENDOTHELIAL CELL PROLIFERATION J. Biol. Chem., March 1, 2002; 277(10): 8388 - 8394. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
